DeepMed Research

Civitas Therapeutics, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Single Ascending Doses of GGF2 in Patients With Left Ventricular Dysfunction and Symptomatic Heart Failure

Phase 1

Completed

Conditions: Heart Failure

Interventions: Drug: Glial growth factor 2/ Neuregulin 1β3
Other: Placebo

First Posted Date: 2010-12-13

Last Posted Date: 2014-07-01

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 40

Registration Number: NCT01258387

Locations: 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
The Medical Group of Saint Joseph's, Atlanta, Georgia, United States

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2008-04-09

Last Posted Date: 2012-03-02

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 177

Registration Number: NCT00654927

Locations: 🇨🇦
St. Michael's Hospital, Toronto, Ontario, Canada
🇺🇸
Shepherd Center, Atlanta, Georgia, United States
🇺🇸
University of Chicago, Chicago, Illinois, United States

and more 19 locations

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR Tablets in Multiple Sclerosis Patients Who Participated in the MS-F203 Trial

Phase 3

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2008-04-01

Last Posted Date: 2012-02-27

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 269

Registration Number: NCT00648908

Locations: 🇺🇸
Advanced Neurology Specialists, Great Falls, Montana, United States
🇺🇸
Ohio State University MS Center, Columbus, Ohio, United States
🇺🇸
University of Texas-Houston, Houston, Texas, United States

and more 29 locations

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Phase 3

Completed

Conditions: Multiple Sclerosis

First Posted Date: 2008-04-01

Last Posted Date: 2012-02-28

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 214

Registration Number: NCT00649792

Locations: 🇺🇸
Shepherd Center, Atlanta, Georgia, United States
🇺🇸
University of Rochester, Rochester, New York, United States
🇨🇦
University of British Columbia, Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

and more 39 locations

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Placebo
Drug: Fampridine-SR

First Posted Date: 2007-06-07

Last Posted Date: 2016-02-04

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 240

Registration Number: NCT00483652

Locations: 🇺🇸
Shepherd Center, Atlanta, Georgia, United States
🇺🇸
Alta Bates Summit Medical Center - Research and Education Institute, Berkeley, California, United States
🇺🇸
CAMC Health Education & Research Institute, Charleston, West Virginia, United States

and more 37 locations

Study of Oral Fampridine-SR in Multiple Sclerosis

Phase 3

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Fampridine-SR
Drug: Placebo

First Posted Date: 2005-08-08

Last Posted Date: 2018-09-11

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 300

Registration Number: NCT00127530

Locations: 🇺🇸
Thomas Jefferson University Physicians, Philadelphia, Pennsylvania, United States
🇺🇸
University of Washington, MS Research Center, Seattle, Washington, United States
🇺🇸
Cleveland Clinical Foundation, Cleveland, Ohio, United States

and more 31 locations

Safety and Efficacy Study of Oral Fampridine-SR in Patients With Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: 10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)
Drug: 15 mg fampridine-SR (4-aminopyridine, 4-AP)
Drug: 20 mg fampridine-SR (4-aminopyridine, 4-AP)
Drug: Placebo

First Posted Date: 2003-01-30

Last Posted Date: 2011-08-04

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 206

Registration Number: NCT00053417

Locations: 🇺🇸
USC MS Comprehensive Care Center, Los Angeles, California, United States
🇺🇸
Shepherd Center, Atlanta, Georgia, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States

and more 22 locations

Safety and Efficacy of Oral Fampridine-SR for the Treatment of Spasticity Resulting From Spinal Cord Injury

Phase 3

Completed

Conditions: Spinal Cord Injury
Muscle Spasticity

Interventions: Drug: Fampridine-SR
Other: Placebo

First Posted Date: 2002-07-16

Last Posted Date: 2020-01-14

Lead Sponsor: Acorda Therapeutics

Target Recruit Count: 213

Registration Number: NCT00041717

Locations: 🇺🇸
Advocate Christ Medical Center-Dept. of Physical Medicine & Rehabilitation-EMG, Oak Lawn, Illinois, United States
🇺🇸
Montana Neuroscience, Missoula, Montana, United States
🇺🇸
Clinical Research Services, Bismarck, North Dakota, United States

and more 42 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy